«We are entirely devoted to prevent, treat and finally hopefully eradicate Alzheimer's disease and other neurodegenerative conditions»
Christoph Hock, MD
An estimated 44 million people of all ages have Alzheimer’s disease (AD) in 2016, and while deaths caused by other major illnesses are continuously declining, deaths caused by neurodegenerative diseases are increasing dramatically. In addition, patient numbers for AD are projected to increase to 115 million by 2050, based on demographic changes in industrialized as well as emerging countries, increasing early diagnoses of these disorders, and increased prevention markets.
Neurimmune aims at the development of disease-modifying treatments for Alzheimer’s disease, and licensed its antibody program Aducanumab (BIIB037) to Biogen and Biogen further acquired rights to BIIB076 from Neurimmune. Neurimmune's pipeline also includes a program in cognitive dysfunction.